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Members of the human epidermal growth factor receptor (HER) family have been of considerable interest in the cancer arena due to
their potential to induce tumorigenesis when their signalling functions are deregulated. The constitutive activation of these proteins is
seen in a number of different common cancer subtypes, and in particular EGFR and HER2 have become highly pursued targets for
anti-cancer drug development. Clinical studies in a number of different cancers known to be driven by EGFR or HER2 show mixed
results, and further mechanistic understanding of drug sensitivity and resistance is needed to realise the full potential of this treatment
modality. Signalling in trans is a key feature of HER family signalling, and the activation of the PI3K/Akt pathway, so critically important
in tumorigenesis, is driven predominantly through phosphorylation in trans of the kinase inactive member HER3. An increasing body
of evidence shows that HER3 plays a critical role in EGFR- and HER2-driven tumours. In particular, HER3 lies upstream of a critically
important tumorigenic signalling pathway with extensive ability for feedback and cross-talk signalling, and targeting approaches that fail
to account for this important trans-target of EGFR and HER2 can be undermined by its resiliency and resourcefulness. Since HER3 is
kinase inactive, it is not a direct target of kinase inhibitors and not presently an easily drugable target. This review presents the current
evidence highlighting the role of HER3 in tumorigenesis and its role in mediating resistance to inhibitors of EGFR and HER2.
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HER FAMILY
The human epidermal growth factor receptor (HER) family of
proteins consisting of EGFR, HER2, HER3, and HER4 are type I
transmembrane growth factor receptors that activate intracellular
signalling pathways in response to extracellular signals. They
consist of an intracellular tyrosine kinase domain, a transmem-
brane domain, and a glycosylated extracellular Ligand-binding
domain. These receptors activate numerous downstream pathways
in response to extracellular ligands, regulating diverse processes
including differentiation, migration, proliferation, and survival. A
distinguishing characteristic of this family is an interdependence
on each other and complementarity in their functions. Indeed
lateral signalling among the HER proteins constitutes a significant
aspect of their signalling functions. Of the four members, HER2
and HER3 are particularly dependent proteins, as they are
functionally incomplete receptors by themselves. HER2 has an
extracellular domain, but appears to lack ligand-binding activity,
while HER3 has a non-functional kinase domain and has no
catalytic kinase activity. However, in complementation, the HER2-
HER3 heterodimer is a highly functional signalling unit and
constitutes the most active signalling dimer in this family,
exemplifying the role of complimentary functions in this complex
receptor family (Tzahar et al, 1996).
The mutational activation of HER family members is seen in
many human malignancies. EGFR is found to be overexpressed in
more than 80% of head and neck cancers, activated by amplification
and/or mutation in approximately 50% of gliomas, activated by
mutation in about 10–15% of non-small cell lung cancers (NSCLC)
in the west, and 30–50% of NSCLCs in Asia (Frederick et al, 2000;
Riely et al, 2006). Amplification and overexpression of HER2 is seen
in about 25–30% of breast cancers and occasionally in other
cancers (Slamon et al, 1989). The mutational activation of HER2 is
also seen in some cancers of the lung (Stephens et al, 2004). In
contrast to the other family members, the current evidence suggests
that HER4 mediates antiproliferative effects; and consistent with
this, HER4 overactivity does not appear to play a major role in
cancer pathogenesis (Sartor et al, 2001; Naresh et al, 2006).
HER2-DRIVEN BREAST CANCER
The best-studied oncogenic model in the HER family has been
HER2-induced breast cancer. The HER2 gene is amplified and
overexpressed in about 25% of breast cancers, conferring a more
aggressive biology (Slamon et al, 1987). The aetiologic role of
HER2 in mammary tumorigenesis has been confirmed by
numerous mouse models of constitutively activated HER2 (or its
rodent counterpart Neu) (Ursini-Siegel et al, 2007; Moasser,
2007a). HER2 overexpression is potently transforming in num-
erous cell culture models and in numerous transgenic mouse models
(Moasser, 2007a). The experimental evidence also suggests that the
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overexpression of HER2 is not only aetiologically important in the
development of mammary carcinoma, but it continues to drive
cancer progression and metastasis in the advanced stages of
cancer. Knockdown of HER2 in HER2-overexpressing cancer cells
induces apoptotic cell death (Roh et al, 2000). In mouse models,
wherein metastatic mammary carcinomas are induced by the
doxycycline induction of Neu overexpression, withdrawal of the
Neu oncogene by cessation of doxycycline therapy results in
complete regression of the mammary tumours and its associated
tumour metastases (Moody et al, 2002). While the simplicity of
each of these model systems understates the complexity of HER2-
overexpressing human breast cancers, it makes a compelling case
that HER2 plays a dominant role in causing and maintaining the
transformed phenotype, thus obligating these model systems to
oncogenic stimulation. The apparent dependency of HER2-over-
expressing tumours on continued HER2 function throughout the
natural course of this cancer has made HER2 an attractive target
for anti-cancer drug development.
MECHANISM OF HER2 TUMORIGENESIS: THE ROLE
OF HER3
The downstream signalling pathways through which HER2 mediates
its tumorigenic functions are complex and have been reviewed
recently (Moasser, 2007a). But importantly, in its overexpressed and
oncogenic state, HER2 does not appear to escape its dependency on
its HER family partners. In particular, an abundance of evidence
reveals that its intimate signalling partner HER3 plays an important
and necessary function in HER2-mediated tumorigenesis. HER3 is
frequently overexpressed in breast cancers with EGFR or HER2
overexpression (Naidu et al, 1998). Tumours arising in mice due to
the transgenic overexpression of Neu are also characterised by
increased expression and phosphorylation of HER3 (Siegel et al,
1999). Increased expression of HER3 synergistically increases the
transforming potency of HER2 (Alimandi et al, 1995). Conversely,
loss of HER3 abolishes the transforming ability of HER2, and
indeed HER3 is in fact an obligate partner in HER2-mediated
transformation (Holbro et al, 2003).
The primary oncogenic signalling apparatus afforded to HER2
by its transphosphorylation of HER3 is the PI3K/Akt pathway.
While HER2 is unable to directly bind PI3K and activate the PI3K/
Akt pathway, the HER2–HER3 signalling complex is highly
effective in doing so. This function is directly mediated through
HER3, which unlike EGFR and HER2, has six tyrosine containing
binding sites for p85, the regulatory subunit of PI3K (Prigent and
Gullick, 1994; Soltoff et al, 1994). The growth factor activation of
PI3K and Akt by HER2 is mediated through the tyrosine
phosphorylation of HER3 (Soltoff et al, 1994). Although immuno-
histochemical reagents are currently unable to directly assay HER3
activity in fixed tissues from clinical studies, the activation of
HER3 in the mouse model of HER2-induced tumours is established
(Siegel et al, 1999). Akt activity, however, can be assayed in clinical
samples, and the clinical data indeed shows frequent activation of
Akt in HER2-expressing tumours (Tokunaga et al, 2006a). The role
of Akt as a critical proliferative and antiapoptotic signal as well as
its contributions to cell invasiveness and metastasis are beyond the
scope of this review. However, a plethora of evidence confirm that
Akt regulates vital cell functions including proliferation, survival,
glucose metabolism, epithelial –mesenchymal transition, genome
stability, and angiogenesis. As such, the HER2-HER3 heterodimer
activates a pathway that lies in the crossroads of oncogenic
signalling and is widely found to be activated in many types of
human cancers.
The role of EGFR in HER2-mediated transformation is less
apparent. EGFR is not always expressed in HER2-amplified breast
cancers and HER2 is fully capable of transforming EGFR-negative
cell models (Chazin et al, 1992).
TARGETING HER PROTEINS
The evidence implicating EGFR and HER2 in cancer pathogenesis
has driven the development of numerous pharmaceutical ap-
proaches to treat cancers using drugs that target EGFR or HER2.
These agents have been widely tested in numerous cancers with
mixed and sometimes unexpected results. While they have clinical
efficacy that is consistent with the scientific evidence showing the
critical role of their targets in some cancer subtypes, such as
certain lung cancers, they also appear to show very limited efficacy
despite compelling scientific evidence predicting otherwise, as in
the case of breast cancer. In other cancer subtypes such as colon
cancers EGFR-targeting agents also show clinical efficacy. How-
ever, a mechanistic basis for this activity is difficult to explain,
since EGFR activation is not commonly seen in colon cancers, and
the clinical activities of EGFR-targeted therapies shows no
correlation with EGFR expression (Chung et al, 2005).
TARGETING HER PROTEINS IN BREAST CANCER
Two modes of targeting HER2 have been extensively studied in the
treatment of HER2-overexpressing breast cancer, both in vitro and
clinically. These include the monoclonal anti-HER2 antibody
trastuzumab and several small molecule tyrosine kinase inhibitors
(TKIs). Trastuzumab induces tumour regression in approximately
30–35% of patients with HER2-amplified metastatic breast cancer
if used as up-front therapy and much less activity if used after other
chemotherapies (Tokunaga et al, 2006b). Understanding resistance
to trastuzumab has been a challenging problem, and this is largely
due to the fact that the mechanisms of response to trastuzumab are
not well understood. Trastuzumab binds to the extracellular
domain of HER2, but extensive efforts have not been able to
determine how and whether this suppresses oncogenic HER2
function (reviewed in Moasser, 2007b). Immunologic targeting may
play a significant part in the mechanism of action of trastuzumab.
The small molecule TKIs have provided a more mechanistically
reliable approach to suppress oncogenic HER2 function. Clinical
efficacy studies have been reported with the EGFR-selective
erlotinib and gefitinib, the EGFR/HER2 selective lapatinib, and
the pan-HER selective canertinib. These agents show only limited
activity as single agents in the treatment of HER2-overexpressing
breast cancer, despite a preponderance of experimental evidence
suggesting that these cancers are highly dependent on HER2
function (Burstein et al, 2004; and reviewed in Moasser, 2007b).
Correlative scientific data from tumour biopsies in some of these
studies confirm that TKIs reach their molecular targets and
suppress the activity of EGFR and HER2 and downstream MAPK
signalling (Spector et al, 2005). Importantly, the inactivation of Akt
signalling is not clearly apparent in these studies, suggesting that
oncogenic HER2 signalling is not completely suppressed by these
therapies. The fact that most HER2-overexpressing breast cancers
fail to respond to TKI therapy is somewhat unexpected, given the
highly abundant and compelling data that shows that these
tumours are driven by and dependent on HER2 function. This has
driven new lines of investigation to determine mechanisms by
which HER2-overexpressing tumours evade drug therapy.
ROLE OF HER3 IN BREAST CANCER DRUG
RESISTANCE
Recent findings in cell-based studies give new insight to the
mechanisms underlying TKI resistance in HER2-driven breast
cancers. Tyrosine kinase inhibitors effectively prevent auto-
phosphorylation of EGFR and HER2 in these tumour cells; however,
the transphosphorylation of HER3 is only transiently suppressed and
HER3 ultimately escapes inhibition by TKIs in HER2-overexpressing
tumour cells (Sergina et al, 2007). The consequence of HER3
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resistance is PI3K/Akt pathway resistance, tumour survival, and
escape from the proapoptotic consequences of the loss of oncogenic
HER2 signalling. The mechanism that underlies HER3 resistance in
these tumours appears to be a forward shift in the phosphorylation-
dephosphorylation equilibrium steady state of HER3 signalling, in
effect buffering HER3 against an incomplete inhibition of HER2
kinase. The resiliency of HER3 is driven by Akt-mediated negative
feedback signaling (Figure 1). The failure to durably suppress HER3
significantly attenuates the anti-tumour activities of TKIs and is
entirely consistent with the limited clinical activities of these agents in
the treatment of HER2-amplified breast cancers. This study also
showed that HER2-driven tumours ultimately cannot escape the total
inactivation of HER2 (Sergina et al, 2007), leaving hope that more
potent TKIs or higher doses of TKIs may yet show significant activity
in this disease. This work also reveals an important and unique
attribute of the HER2–HER3 signalling complex. The fact that
catalytic kinase activity and signalling activity are embodied within
different members in this signalling complex confers upon it an extra
level of regulation. The additional level of regulation makes it
considerably more difficult to suppress HER2 oncogenic signalling
with TKIs. The HER2–HER3 complex presents a considerable
challenge to drug therapy, since in this complex, HER3 is the
principle mediator of resistance, yet HER3 is kinase inactive and is
not a direct target of TKIs. In fact, since the signalling function of
HER3 is mediated through its role as a substrate of HER2 and a
scaffold for recruitment of signalling proteins, it presents a difficult
target to inactivate by current pharmaceutical approaches.
TARGETING HER PROTEINS IN NSCLC
The broad testing of EGFR-selective TKIs in cancers revealed a small
subset of highly responsive lung cancer patients (Fukuoka et al,
2003). Subsequent studies have identified this subset as patients with
cancers driven by mutationally activated EGFR (Lynch et al, 2004).
Lung cancers driven by mutated EGFR are highly responsive to TKI
therapy (Jackman et al, 2006). The acquisition of TKI resistance in
these patients appears to correlate, in part, with the development of
kinase domain mutations that confer resistance to TKI therapy
(Kobayashi et al, 2005). The identification of EGFR mutations in
lung cancer has led to an explosion of interest in studying the
mechanisms underlying lung cancer pathogenesis, focusing on the
role of HER family proteins. An important role for the kinase-
inactive HER3 has also emerged in this disease. Characterisation of
lung cancers with TKI-sensitive EGFR mutations reveals that PI3K/
Akt pathway in these tumours is dependent on HER3 signalling
(Engelman et al, 2005). This is analogous to breast cancers with
HER2 overexpression, which also depend on HER3 signalling for the
activation of PI3K/Akt signalling, discussed above. Tyrosine kinase
inhibitor therapy of TKI-sensitive lung cancers inactivates HER3
signalling and downstream PI3K/Akt signalling, but HER3 signalling
in TKI-resistant lung cancers appears to be uncoupled from EGFR
and resistant to inactivation by TKIs (Engelman et al, 2005). The
development of the EGFR T790M mutation in lung cancers confers
drug resistance and is associated with persistent activation of HER3/
PI3K/Akt signalling (Engelman et al, 2006). The constitutive
activation of HER3 signalling in TKI-resistant lung cancers can
also be mediated through the amplification of MET, recently
identified in certain TKI-resistant subclones of lung cancer cells
(Engelman et al, 2007) (Figure 1). Thus the critical role of HER3 as a
mediator of the oncogenic functions of the HER family is gradually
but surely coming to light in the case of lung cancers.
TARGETING HER PROTEINS IN MALIGNANT
GLIOMAS
EGFR is overexpressed in 40– 50% of glioblastoma multiforme
(GBM). Of these tumours, nearly half express the EGFRvIII
mutation, which is an in-frame deletion of exons 2–7 from the
extracellular domain that leads to a constitutively activated
receptor (Shinojima et al, 2003). Barriers to effective drug
biodistribution in the CNS compartment make this disease more
challenging for systemic therapy modalities. But there is evidence
from phase I studies that HER family TKIs are active in the
treatment of this disease (Prados et al, 2006). Molecular
determinants of treatment response have been studied in patients
with GBM. The deletion of PTEN is common in GBMs and
correlates with resistance to TKI therapy, and conversely the co-
expression of PTEN with EGFRvIII identifies erlotinib-responsive
patients (Mellinghoff et al, 2005). The effect of PTEN deletion in
this pathway is the constitutive activation of downstream Akt
signalling. By removing the negative regulation of phosphoino-
sitide signalling, PTEN deletion uncouples HER3 from the Akt
pathway, rendering HER family-driven tumours resistant to HER
TKIs. This has been demonstrated through the restoration of TKI
sensitivity by inducible re-expression of PTEN in PTEN-null
tumour cells (She et al, 2003). Since the inactivation of PTEN
activates Akt signalling at a point downstream of HER3, a role for
HER3 in mediating drug resistance in PTEN-deleted tumours may
be redundant. The role of HER3 in gliomagenesis and in response
and resistance of GBMs to TKI therapy awaits more studies.
FUTURE DIRECTIONS IN TARGETING HER PROTEINS
Much of the studies of the past decade have focused on the
oncogenic functions inherent in the deregulated catalytic kinase
activities of EGFR and HER2. Signalling in trans is a key feature of
HER family signalling, and although this attribute of HER family
signalling has been appreciated for a number of years, the
continued dependency of tumours on HER family trans-signalling
is just now becoming more apparent. In particular, the emerging
role of HER3 in mediating de novo or acquired drug resistance has
shifted the focus on this critically important lateral signalling
partner of EGFR and HER2 and its pivotal role in driving PI3K/Akt
signalling. The increasing awareness of the role of HER3 in cancer
progression and drug resistance has two implications for future
directions. First of all, the correlation of HER3 signalling with
response and resistance suggests that HER3 is a much more
suitable biomarker to guide the efficacy of treatments compared
with more current studies that rely mostly on the autophos-
phorylation activities of EGFR or HER2. Second, the identification
of HER3 as a focal point in response and resistance to TKI therapy
identifies it as a novel target for newer anti-cancer agents that can
potentially overcome TKI resistance. However, HER3 is a
considerably challenging target for pharmaceuticals. Unlike EGFR
or HER2, it lacks catalytic kinase activity and its signalling
functions cannot be inhibited by TKIs and it is not a direct target
of this class of agents. Its signalling functions do include ligand
binding, and although antibody therapeutics can be developed to
bind its extracellular domain and interfere with ligand binding, it
is not clear whether the oncogenic functions of activated EGFR or
HER2 are driven by extracellular ligands. The principle signalling
function of HER3 in cancers appears to be its role as a substrate of
EGFR or HER2 and a scaffold for the recruitment of cytosolic
signalling proteins. Targeting scaffold functions remain a challen-
ging goal for current pharmaceutical technologies. The more
realistically drugable targets are the ones immediately downstream
of HER3. Since the weight of current evidence suggests that the
predominant oncogenic function of HER3 is its ability to activate
PI3K and Akt signalling, then it is a reasonable hypothesis that
inhibitors of PI3K or Akt can also abrogate HER3 signalling and
can potentially be used in combination with HER TKIs to develop
much more effective therapies or to overcome HER TKI resistance.
However, since PI3K and Akt mediate many signalling pathways
important for numerous cellular functions in normal tissues, it
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remains to be determined whether these agents have sufficiently
wide therapeutic index to be used in the treatment of cancer. The
development and testing of such agents are actively being pursued
in the pharmaceutical sector.
Although EGFR and HER2 have been viewed as prototype
oncogenes that can drive tumorigenesis through their constitutive
activation in cancers, evidence is mounting that their trans-
signalling functions are essential aspects of their oncogenic
functions. This has highlighted the role of their most active
trans-signalling partner HER3. The ability of HER3 to escape drug
therapy, its resiliency and resourcefulness, and the multitude of
feedback and crosstalk mechanisms that appear to come into play
to ensure persistent tumour HER3 signalling activity despite the
suppression of EGFR or HER2 by targeted therapies identifies
HER3 as a focal point in HER family-induced transformation and a
new biomarker and target for future cancer therapies.
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